iRadimed (NASDAQ:IRMD – Get Free Report) and Jushi (OTCMKTS:JUSHF – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation and profitability.
Valuation and Earnings
This table compares iRadimed and Jushi”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| iRadimed | $86.34 million | 12.18 | $22.48 million | $1.79 | 45.93 |
| Jushi | $262.91 million | 0.32 | -$68.59 million | ($0.34) | -1.22 |
Analyst Ratings
This is a breakdown of recent recommendations for iRadimed and Jushi, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| iRadimed | 0 | 1 | 3 | 1 | 3.00 |
| Jushi | 0 | 0 | 1 | 0 | 3.00 |
iRadimed currently has a consensus target price of $120.00, indicating a potential upside of 45.95%. Given iRadimed’s higher possible upside, equities analysts plainly believe iRadimed is more favorable than Jushi.
Institutional and Insider Ownership
92.3% of iRadimed shares are owned by institutional investors. Comparatively, 21.7% of Jushi shares are owned by institutional investors. 34.6% of iRadimed shares are owned by insiders. Comparatively, 23.1% of Jushi shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Profitability
This table compares iRadimed and Jushi’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| iRadimed | 26.70% | 23.45% | 20.36% |
| Jushi | -24.44% | N/A | -15.46% |
Volatility and Risk
iRadimed has a beta of 0.89, indicating that its share price is 11% less volatile than the S&P 500. Comparatively, Jushi has a beta of -0.63, indicating that its share price is 163% less volatile than the S&P 500.
Summary
iRadimed beats Jushi on 13 of the 14 factors compared between the two stocks.
About iRadimed
IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.
About Jushi
Jushi Holdings Inc., a vertically integrated cannabis company, engages in the cultivation, processing, retail, and distribution of cannabis for medical and adult-use markets. The company offers flower, extracts, concentrates, edibles, oil, pre-rolls, tinctures, capsules, softgels, cannabis-infused gummies and ultra-premium chocolate, and topicals products, as well as vaporization devices and cartridges under The Bank, The Lab, Nira+ Medicinals, Sèchè, Tasteology, and Hijinks brands. It is also involved in the bulk wholesale of refined cannabinoids and terpenes. In addition, the company operates medical cannabis dispensaries under the BEYOND/HELLO, Nature’s Remedy, and NuLeaf brands. It markets its products to local dispensaries and large multi-state operators. The company is headquartered in Boca Raton, Florida.
Receive News & Ratings for iRadimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iRadimed and related companies with MarketBeat.com's FREE daily email newsletter.
